TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03578042

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care
Description: any free triple combination therapy for hypertension given as 2 or 3 pills
Study: NCT03223662

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Esophagectomy
Description: Minimally-invasive esophagectomy (RAMIE) or traditional open approach if necessary.
Study: NCT00728897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 new formulation
Description: GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
Study: NCT01254370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: 0.005%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travatan Z
Description: 0.004%
Study: NCT01703468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Study: NCT04283318

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12h fasting
Description: 12h fasting (overnight)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12h fasting
Description: 12h fasting (overnight)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12h fasting
Description: 12h fasting (overnight)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12h fasting
Description: 12h fasting (overnight)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 36h fasting
Description: 36h fasting ( one day and two nights fasting)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 36h fasting
Description: 36h fasting ( one day and two nights fasting)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 36h fasting
Description: 36h fasting ( one day and two nights fasting)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 36h fasting
Description: 36h fasting ( one day and two nights fasting)
Study: NCT00802971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FOS
Description: Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
Study: NCT02726347

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV-23
Description: one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV-23
Description: one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV-23
Description: one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV-23
Description: one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV-23
Description: one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
Study: NCT00570947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR Anytime Kit
Description: The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
Study: NCT01350219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator
Description: For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 \~ 9 hrs.
Study: NCT02937597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePBP: eProficiency Based Progression
Description: National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eS: eScenarios
Description: National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HSE
Description: National HSE e-learning programme only
Study: NCT01777841

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Care plan delivery

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Study: NCT01565577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenbVac
Description: Blood test
Study: NCT02444026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT for Insomnia
Description: Internet-delivered Cognitive Behavioural Therapy for Insomnia
Study: NCT02149134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TeHF2013-01
Study: NCT03012646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil (6 mcg/breath) administered four times daily
Study: NCT02333643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle topical
Study: NCT03678077

Intervention type: OTHER
Intervention: Mild traumatic brain injury
Description: This is a register based observational study and does not include interventions. Exposure is mild traumatic brain injury.
Study: NCT06522113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: patients were given cilostazol 100mg twice a day with aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: patients were given clopidogrel 75mg with aspirin
Study: NCT00761878

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to plasma energy
Description: Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
Study: NCT03886272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357 (Test)
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357 (Reference)
Description: tablet
Study: NCT00325416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: (Days -4,-3,-2) 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Description: (Days -4,-3,-2) 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan (TPT)
Description: Phase I Dose Escalation: Level 1 - 20 mg/m\^2; Level 2 - 30 mg/m\^2; Level 4 - 54 mg/m\^2; Level 5 - 72 mg/m\^2; Level 6 - 96 mg/m\^2; Level 7 - 127.8 mg/m\^2; Level 8 - 170.1 mg/m\^2~Phase II: Treatment at maximum tolerated dose (MTD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan (TPT)
Description: Phase I Dose Escalation: Level 1 - 20 mg/m\^2; Level 2 - 30 mg/m\^2; Level 4 - 54 mg/m\^2; Level 5 - 72 mg/m\^2; Level 6 - 96 mg/m\^2; Level 7 - 127.8 mg/m\^2; Level 8 - 170.1 mg/m\^2~Phase II: Treatment at maximum tolerated dose (MTD)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Rescue
Description: Day 0

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cell Rescue
Description: Day 0
Study: NCT01299909

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Training for Smokers
Description: 8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training for Smokers
Description: 8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quitline
Description: Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
Study: NCT05217030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal assisted therapy
Description: Patients in AAT group had handler place dog on bed and patient's hand was placed on dog. Bedside RN measured GCS, RLAS, LoCmds before and after intervention
Study: NCT00728897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 new formulation
Description: GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 new formulation
Description: GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
Study: NCT02524938

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorogenic Acid (CGA) enriched coffee
Description: Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.~Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Conventional coffee
Description: Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
Study: NCT01737801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung function test
Description: Lung function test.
Study: NCT00728897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 new formulation
Description: GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 new formulation
Description: GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 old formulation
Description: GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 old formulation
Description: GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 old formulation
Description: GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
Study: NCT02868515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot cereal contain 3 g dietary fiber
Description: Intervention involves consumption of a hot cereal over 14 day period
Study: NCT03238131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole
Study: NCT00728897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 old formulation
Description: GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 old formulation
Description: GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
Study: NCT03238131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
Study: NCT00728897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 old formulation
Description: GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
Study: NCT02601300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Study: NCT02072785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Study: NCT01258842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019
Description: B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachet, consumed once per day for 12 weeks
Study: NCT01691170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Hamstring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps Strengthening
Study: NCT02611336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil 20 mg to be taken orally once daily, for 3 months
Study: NCT02791178

Intervention type: PROCEDURE
Intervention: Optical coherence tomography (OCT)
Description: Special camera to study part of your heart that was affected

Intervention type: PROCEDURE
Intervention: Index of microcirculatory resistance (IMR)
Description: Special wire to study part of your heart that was affected

Intervention type: OTHER
Intervention: Cardiac MRI
Description: Special scanner if the heart to assess the damage of your heart
Study: NCT03122223

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438)
Description: expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer greater than or equal to 1 × 10\^6 cell culture infectious dose (CCID)50 and less than 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438)
Description: expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer greater than or equal to 1 × 10\^6 cell culture infectious dose (CCID)50 and less than 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438)
Description: expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer greater than or equal to 1 × 10\^6 cell culture infectious dose (CCID)50 and less than 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.
Study: NCT03238131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
Study: NCT02493959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PYY1-36 infusion
Description: Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PYY1-36 + sitagliptin
Description: Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PYY3-36 infusion
Description: 0.8 pmol/kg/min infusion of PYY3-36.
Study: NCT03122223

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent subtype C gp120/MF59
Description: clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered IM as a single 0.5 mL dose.
Study: NCT02493959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Infusion of saline for 2 hrs.
Study: NCT01414244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glutamine
Description: Drug
Study: NCT00742950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal 2.8-mm corneal incision
Description: Phacoemulsification through a nasal 2.8-mm incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporal 2.8-mm corneal incision
Description: Phacoemulsification through a 2.8-mm temporal incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior 2.8-mm incision
Description: Phacoemulsification through a superior 2.8-mm corneal incision
Study: NCT00523211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: One tablet of vicriviroc 30 mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of placebo once daily.
Study: NCT03122223

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent subtype C gp120/AS01(B)
Description: clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 20 mcg or 100 mcg, mixed with AS01B adjuvant, administered IM as a single 0.75 mL dose.
Study: NCT02258672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation program
Description: Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
Study: NCT04894708

Intervention type: PROCEDURE
Group type: OTHER
Intervention: colonoscopy
Description: addition of polyp detection algorithm by Fujifilm

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: colonoscopy
Description: addition of polyp detection algorithm by Fujifilm
Study: NCT03122223

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent subtype C gp120/AS01(B)
Description: clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 20 mcg or 100 mcg, mixed with AS01B adjuvant, administered IM as a single 0.75 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9%, administered IM.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9%, administered IM.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9%, administered IM.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9%, administered IM.
Study: NCT01941433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arthritis Health Journal

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Arthritis Health Journal
Study: NCT03835351

Intervention type: DEVICE
Group type: OTHER
Intervention: Urinary Catheter
Description: An intraoperative urinary catheter will be inserted which will be taken out at the end of the case
Study: NCT02854787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: A bolus of 100 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: A bolus of 0,2 mcg/kg
Study: NCT03644303

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT + ADT
Description: Short course SBRT to 1 or 2 oligo-progressing metastases in addition to continued abiraterone or enzalutamide
Study: NCT03032432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Elastic Garment (DEG) brace
Description: Improve function of the shoulder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Injection to improve rotator cuff tendinosis pain and functional score

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: Injection to improve rotator cuff tendinosis pain and functional score
Study: NCT01034163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02185001

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Medial Patellofemoral Ligament (MPFL) Repair
Description: The MPFL will be repaired directly at the site of the traumatic injury.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Patellar immobilization, stabilization, and strengthening under the direction and guidance of the physician and physical therapist.